M28 Capital Management’s BridgeBio Pharma BBIO Stock Holding History

M28 Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-121,200	Closed	-$4.19M	–	10
2025 Q1	$4.19M	Hold	121,200	–	–	5.74%	4
2024 Q4	$3.33M	Hold	121,200	–	–	3.27%	7
2024 Q3	$3.09M	Hold	121,200	–	–	3.39%	8
2024 Q2	$3.07M	Hold	121,200	–	–	3.98%	7
2024 Q1	$3.75M	Hold	121,200	–	–	2.77%	8
2023 Q4	$4.89M	Hold	121,200	–	–	4.05%	7
2023 Q3	$3.2M	Sell	121,200 -45,000	-27%	-$1.28M	3.67%	6
2023 Q2	$2.86M	Sell	166,200 -138,500	-45%	-$2.08M	3.78%	9
2023 Q1	$5.05M	Sell	304,700 -114,300	-27%	-$1.33M	5.71%	6
2022 Q4	$3.19M	Sell	419,000 -94,300	-18%	-$903K	3.04%	8
2022 Q3	$5.1M	Buy	513,300 +47,100	+10%	+$489K	5.33%	5
2022 Q2	$4.23M	Hold	466,200	–	–	4.75%	5
2022 Q1	$4.73M	Hold	466,200	–	–	4.35%	8
2021 Q4	$7.78M	Buy	+466,200	New	+$19.7M	6.07%	7

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

M28 Capital Management's BBIO Position: Q2 2025 in Review

M28 Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 121,200 shares — an estimated $4.19M sold.

M28 Capital Management first reported a position in BBIO in Q4 2021 and held it in 14 quarters. The position peaked at $7.78M in Q4 2021. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

M28 Capital Management reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
M28 Capital Management sold 121,200 BridgeBio Pharma shares in Q2 2025, an estimated $4.19M.
M28 Capital Management first reported a position in BridgeBio Pharma in Q4 2021 and held it in 14 quarters.
M28 Capital Management's BridgeBio Pharma position peaked at $7.78M in Q4 2021.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on M28 Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.